黑腹果蝇保幼激素受体Met泛素化修饰位点预测及功能验证

目的预测黑腹果蝇保幼激素(juvenile hormone,JH)受体Methoprene tolerant(Met)的泛素化修饰位点,并验证其功能。方法利用UbPred和CKSAAP_UbSite在线预测工具对Met的泛素化位点进行预测;通过重叠PCR技术将预测的各泛素化修饰位点赖氨酸分别突变为丙氨酸,同时将第46和526位赖氨酸突变为丙氨酸;将突变后的Met插入至表达载体p Ac5. 1/V5-His B中,构建各位点突变的表达质粒;转染果蝇Kc细胞,并经格尔德霉素(geldanamycin,GA)处理,Western blot法检测各位点突变后Met的表达。结果根据UbPred和CKSAAP_UbSite在线网站预测结果,选取7个赖氨酸位点作为Met的潜在泛素化修饰位点,CKSAAP_UbSite及UbPred预测分值最高的分别为第46和526位赖氨酸。构建的Met各位点突变表达质粒转染果蝇Kc细胞后,于相对分子质量约82 000处均可见Met目的蛋白的表达,经GA处理后,Met表达下降。结论成功构建了Met的7个预测泛素化修饰位点的单突变表达质粒及1个双突变表达质粒,这些位点的突变均不足以抑制GA诱导Met的降解。     

CAST基因多态性与西门塔尔杂交牛胴体和肉质性状的相关性分析

目的分析钙蛋白酶抑制蛋白(Calpastatin,CAST)基因多态性与西门塔尔杂交牛胴体和肉质性状的相关性。方法选取95头西门塔尔杂交牛,采用限制性片段长度多态性聚合酶链反应(Restriction fragment length polymor-phism-polymerase chain reaction,RFLP-PCR)对CAST基因外显子1(Exon1)和外显子5(Exon5)区域的片段的多态性进行检测,并对突变位点与西门塔尔肉牛胴体和肉质性状的相关性进行分析。结果在所分析的片段中,仅引物4扩增的片段(Exon1)存在一个G→C碱基的置换突变(E1 256 g﹥c),为同义突变;该突变位点为RasⅠ酶的自然酶切位点,酶切后存在GG、GC和CC 3种基因型,CC基因型与西门塔尔牛的净肉率性状显著相关(P﹤0.05),而对其他胴体和肉质性状无显著影响。结论 CAST基因Exon1处存在的突变位点与西门塔尔肉牛的净肉率显著相关,因此该位点将有助于筛选与牛肉质相关的辅助选择标记,该基因将为鉴定与肉质相关的功能基因提供参考。     

天蚕素A-蛙皮素杂合肽突变体的构建、表达及其抗菌活性

目的构建天蚕素A(1～8)-蛙皮素(1～12)杂合基因抗菌肽(CA-MA杂合肽)突变体,在大肠杆菌中融合表达,并进行抗菌活性检测。方法采用PCR体外定点突变技术,设计1对方向相反的引物,其中1个引物引入突变点,应用高保真的PolybestDNA多聚酶进行重组表达质粒pGEX-4T-1-CA-MA的PCR扩增,使CA-MA杂合肽第16位密码子由AGT突变为TGG。将扩增片段自身连接,构建CA-MA杂合肽突变重组表达质粒pGEX-4T-1-W16-CA-MA,转化E.coliBL21,IPTG诱导表达突变体蛋白W16-CA-MA,并对表达产物进行纯化。分离GST融合蛋白后,进行抗菌活性检测。结果重组突变表达质粒DNA测序结果表明,在预期位点发生了突变;突变蛋白在大肠杆菌中的表达量约占菌体总蛋白的18%;纯化后蛋白纯度可达75%以上,并具有一定的抗菌活性。结论已成功获得了具有抗菌活性的杂合肽突变体W16-CA-MA。     

产气荚膜梭菌α毒素基因PLC-Asp56定点突变及其特性鉴定

本实验通过对A型产气荚膜梭菌α毒素PLC基因第56位氨基酸进行定点突变,将天冬氨酸Asp突变为丙氨酸Ala,构建了含有PLC-Asp56Ala突变基因的表达质粒,测序结果表明,重组质粒pPLC-Asp56Ala已经含有α毒素PLC基因的PLC-Asp56Ala突变基因。经聚丙烯酰胺凝胶电泳分析,PLC-Asp56Ala突变体蛋白含量占菌体总蛋白相对含量的22.48%。二级结构预测结果表明PLC-Asp56Ala突变体蛋白的二级结构第55位和第56位突变位点相对于α毒素由原来的无规则卷曲变成β转角。生物学活性检测表明PLC-Asp56Ala突变体蛋白已经完全丧失该酶活性。本研究结果可为今后对A型产气荚膜梭菌α毒素的致病机制的探究提供基础理论依据。     

冷应激大鼠体内miR-383-5p表达的变化及其功能的预测分析

目的探讨冷应激大鼠体内miR-383-5p表达的变化,并对其功能进行预测分析。方法将大鼠置(4±0. 05)℃冷暴露12 h,同时设对照组(24℃常温饲养),qRT-PCR法检测miR-383-5p在血清和肝脏中的表达水平。应用miRanda、TargetScan和miRDB 3种软件同时对miR-383-5p进行靶基因预测,并通过DAVID 6. 8软件对miR-383-5p肝脏靶基因进行GO和KEGG分析。qRT-PCR和Western blot法检测下调BRL-3A细胞中miR-383-5p表达对部分代谢相关靶基因mRNA转录及蛋白表达的影响。结果冷应激后小鼠血清及肝脏中的miR-383-5p相对表达量均显著下降(P 0. 05)。生物信息学方法预测出733个在大鼠肝脏表达的靶基因,GO富集分析结果显示这些靶基因主要与细胞氧化还原过程、增殖和凋亡相关,KEGG分析结果显示富集靶基因最多的信号通路是代谢通路。下调miR-383-5p表达使BRL-3A细胞中Mtor、Pfkfb1和Apbb3基因的mRNA的转录水平显著升高(P 0. 05),Pfkfb1蛋白的表达量显著升高(P 0. 05)。结论冷应激可降低大鼠肝脏中miR-383-5p的表达量,进而通过调节Pfkfb1等靶基因的表达参与细胞的代谢、增殖和凋亡。     

人乌头酸脱羧酶1基因及其编码蛋白的生物信息学分析

目的 对人乌头酸脱羧酶1(aconitate decarboxylase 1,ACOD1)基因的转录调控因素及其编码蛋白的分子功能进行分析。方法 采用多种生物信息学软件对人ACOD1基因启动子区域转录因子结合位点、甲基化CpG位点、单核苷酸多态性（singlenucleotide polymorphism,SNP）位点进行预测,对人ACOD1基因编码的蛋白进行GO(Gene Onotology)蛋白功能注释分析及蛋白互作网络分析。结果 人ACOD1基因启动子区域存在3个启动子序列,17个转录因子结合位点,无甲基化CpG位点,并存在12个SNP位点;人ACOD1蛋白具有多种分子功能并参与多种生物过程,可能与白细胞介素-1β(interleukin-1 beta,IL-1β)、C-C基序趋化因子-4(C-C motif chemokine-4,CCL-4)、干扰素调节因子1(interferon regulatory factor 1,IRF1)和C-X-C基序趋化因子10(C-X-C motif chemokine 10,CXCL10)等蛋白具有相互作用关系。结论 本文为进一步研究人AC...     

登革病毒1型Ⅰ～Ⅴ基因亚型的基因组差异分析

目的分析登革病毒1型(Dengue virus type 1,DENV-1)Ⅰ～Ⅴ基因亚型基因组全长核苷酸及氨基酸序列差异。方法通过GenBank搜索DENV-1 5个不同基因亚型的全长基因组序列,获得其相应的氨基酸序列。采用BIOEDIT软件,统计基因亚型间核苷酸突变和氨基酸替代位点,分析其相似度,通过RNA二级结构在线预测网站预测DENV-1不同亚型间3′UTR的二级结构差异,蛋白结构在线预测网站预测主要流行于中国的Ⅰ及ⅤDENV-1基因亚型结构蛋白的二级结构,对其氨基酸组成及编码序列中可能存在的蛋白结合区域等进行差异分析。结果DENV-1 5个基因亚型核苷酸相似性为91. 40%～94. 50%,氨基酸序列相似性为97. 11%～98. 38%,5个基因亚型各自编码3 392个氨基酸,其中共有195个位点有氨基酸的变化。DENV-1不同亚型的3′UTR的二级结构各不相同。DENV-1基因型为Ⅰ、Ⅴ的775个氨基酸中占组成比例最多的均是苏氨酸(T),Ⅰ型可能的蛋白结合位点有26个,多聚核苷酸结合位点有9个。Ⅴ型可能的蛋白结合位点有24个,多聚核苷酸结合位点有7个。他们均有相同数量的螺旋和跨膜螺旋。结论通过对DENV-1 5个不同的基因亚型的全长核苷酸和氨基酸序列的比较分析,及Ⅰ、Ⅴ基因亚型结构蛋白二级结构的预测,为研究DENV-1不同基因型之间的生物学和致病性差异提供参考。     

人内皮抑素基因的定点突变及其在大肠杆菌中的表达

目的对人内皮抑素(hES)基因进行定点突变,提高其在大肠杆菌中的可溶性表达量。方法根据Internet网站提供的关于hES的结构信息及其结构与功能方面的研究文献,设计突变位点;利用生物信息学的相关网站,对hES突变体进行结构预测,验证突变位点设计的合理性;采用重叠延伸PCR方法进行hES基因的定点突变,并将突变基因和未突变基因分别亚克隆至表达载体pGEX-4T-3,在大肠杆菌中进行融合表达,比较突变前后目的蛋白的可溶性表达量。结果三级结构预测结果表明突变位点设计合理,序列分析结果表明实现了hES基因的定点突变。突变基因的表达产物中,可溶性部分约占总表达量的40%,而未突变基因的表达产物几乎全部为包涵体。结论已成功对hES基因进行了定点突变,突变后的hES可溶性表达量得到了提高。     

东南亚地区寨卡病毒的流行及结构蛋白分子进化特征分析

目的分析寨卡病毒(Zika virus,ZIKV)在东南亚地区的感染传播情况,探讨其分子水平上的进化特征。方法用关键词和主题词检索ZIKV在东南亚地区暴发感染流行情况。在GenBank中获取ZIKV东南亚病毒株全基因序列,采用BIOEDIT软件进行比对;利用MEGA 7. 0软件绘制系统进化树;将结构蛋白核苷酸翻译获得其相应的氨基酸序列,分析突变情况;统计不同株型间结构蛋白核苷酸突变和氨基酸替代位点;预测包膜蛋白第三结构域(envelop domainⅢ,ED-Ⅲ)的二级结构。结果 ZIKV在东南亚国家均有血清学感染或回顾性检测阳性报道,其中越南、泰国和新加坡ZIKV感染病例较多,疾病负担较为严重。系统进化树表明,东南亚ZIKV株均属于亚洲型,2016年新加坡株(序列号:KY241788)与2015年巴西株亲缘关系最近,1966年分离的马来西亚株与其他东南亚株亲缘关系较远。东南亚ZIKV各株型间衣壳蛋白(capsid protein,C)的碱基突变点为22处,突变率为6. 36%,造成非同义氨基酸突变点为19处,突变率为16. 52%。前膜蛋白(pre-membrane protein,prM)的碱基突变点为51处,突变率为10. 12%,造成非同义氨基酸突变点为37处,突变率为22. 02%。包膜蛋白(envelope protein,E)的碱基突变点为141处,突变率为9. 33%,造成非同义氨基酸突变点为101处,突变率为20. 04%。ED-Ⅲ二级结构预测结果显示,在该区域2株代表株有相同数量的蛋白结合位点,代表株2(1966 Malaysia KX377336)存在1个蛋白结合位点富集区(ED-Ⅲ:55-63),而代表株1(2014 Thailand KU681081)蛋白结合位点分布较均匀,代表株2的ED-Ⅲ存在1个二硫键,而代表株1不存在,代表株1(ED-Ⅲ:79-80)存在1个解螺旋,而代表株2不存在。结论通过病例统计分析、系统发育分析、蛋白质核苷酸及氨基酸序列比较分析、ED-Ⅲ二级结构预测,为研究东南亚地区ZIKV不同株型间的生物学和流行致病性差异提供参考。     

籽鹅卵巢产蛋性能相关基因全长cDNA序列的克隆与分析

目的克隆并分析籽鹅卵巢产蛋性能相关基因EST1的全长cDNA序列。方法利用实时荧光定量PCR技术对EST1基因在籽鹅产蛋前期与产蛋期卵巢中mRNA表达水平进行检测,并采用RACE(Rapid amplification of cDNAends,RACE)技术对该基因全长cDNA序列进行克隆,应用生物信息学预测方法对其编码的蛋白质进行分析。结果籽鹅产蛋期卵巢组织中EST1基因mRNA的表达水平显著高于产蛋前期(P<0.05)。经RACE技术获得EST1基因全长cDNA序列长1715bp,具有单一的完整开放阅读框(ORF,14～1318bp),推测编码蛋白含434个氨基酸残基,相对分子质量为107100,等电点为5.00。该蛋白为细胞质内蛋白,含3个跨膜螺旋,蛋白序列中含1个信号肽切割位点。结论经分子生物学软件进行蛋白质功能预测,初步确定EST1基因为籽鹅α-烯醇化酶蛋白基因,推测该基因可能参与籽鹅产蛋性能的分子调控。     

CRISPR/Cas9-Mediated Allele-Specific Disruption of a Dominant COL6A1 Pathogenic Variant Improves Collagen VI Network in Patient Fibroblasts

Collagen VI-related disorders are the second most common congenital muscular dystrophies for which no treatments are presently available. They are mostly caused by dominant-negative pathogenic variants in the genes encoding α chains of collagen VI, a heteromeric network forming collagen; for example, the c.877G>A; p.Gly293Arg COL6A1 variant, which alters the proper association of the tetramers to form microfibrils. We tested the potential of CRISPR/Cas9-based genome editing to silence or correct (using a donor template) a mutant allele in the dermal fibroblasts of four individuals bearing the c.877G>A pathogenic variant. Evaluation of gene-edited cells by next-generation sequencing revealed that correction of the mutant allele by homologous-directed repair occurred at a frequency lower than 1%. However, the presence of frameshift variants and others that provoked the silencing of the mutant allele were found in >40% of reads, with no effects on the wild-type allele. This was confirmed by droplet digital PCR with allele-specific probes, which revealed a reduction in the expression of the mutant allele. Finally, immunofluorescence analyses revealed a recovery in the collagen VI extracellular matrix. In summary, we demonstrate that CRISPR/Cas9 gene-edition can specifically reverse the pathogenic effects of a dominant negative variant in COL6A1.     

Four Novel p.N385K,p.V36A,c.1033–1034insT and c.1417–1418delCT Mutations in the Sphingomyelin Phosphodiesterase 1 (SMPD1) Gene in Patients with Types A and B Niemann-Pick Disease (NPD)

Background: Types A and B Niemann-Pick disease (NPD) are autosomal-recessive lysosomal storage disorders caused by the deficient activity of acid sphingomyelinase due to mutations in the sphingomyelin phosphodiesterase 1 (SMPD1) gene. Methods: In order to determine the prevalence and distribution of SMPD1 gene mutations, the genomic DNA of 15 unrelated Iranian patients with types A and B NPD was examined using PCR, DNA sequencing and bioinformatics analysis. Results: Of 8 patients with the p.G508R mutation, 5 patients were homozygous, while the other 3 were heterozygous. One patient was heterozygous for both the p.N385K and p.G508R mutations. Another patient was heterozygous for both the p.A487V and p.G508R mutations. Two patients (one homozygous and one heterozygous) showed the p.V36A mutation. One patient was homozygous for the c.1033–1034insT mutation. One patient was homozygous for the c.573delT mutation, and 1 patient was homozygous for the c.1417–1418delCT mutation. Additionally, bioinformatics analysis indicated that two new p.V36A and p.N385K mutations decreased the acid sphingomyelinase (ASM) protein stability, which might be evidence to suggest the pathogenicity of these mutations. Conclusion: with detection of these new mutations, the genotypic spectrum of types A and B NPD is extended, facilitating the definition of disease-related mutations. However, more research is essential to confirm the pathogenic effect of these mutations.     

Intracellular and Extracellular Markers of Lethality in Osteogenesis Imperfecta: A Quantitative Proteomic Approach

Osteogenesis imperfecta (OI) is a heritable disorder that mainly affects the skeleton. The inheritance is mostly autosomal dominant and associated to mutations in one of the two genes, COL1A1 and COL1A2, encoding for the type I collagen α chains. According to more than 1500 described mutation sites and to outcome spanning from very mild cases to perinatal-lethality, OI is characterized by a wide genotype/phenotype heterogeneity. In order to identify common affected molecular-pathways and disease biomarkers in OI probands with different mutations and lethal or surviving phenotypes, primary fibroblasts from dominant OI patients, carrying COL1A1 or COL1A2 defects, were investigated by applying a Tandem Mass Tag labeling-Liquid Chromatography-Tandem Mass Spectrometry (TMT LC-MS/MS) proteomics approach and bioinformatic tools for comparative protein-abundance profiling. While no difference in α1 or α2 abundance was detected among lethal (type II) and not-lethal (type III) OI patients, 17 proteins, with key effects on matrix structure and organization, cell signaling, and cell and tissue development and differentiation, were significantly different between type II and type III OI patients. Among them, some non–collagenous extracellular matrix (ECM) proteins (e.g., decorin and fibrillin-1) and proteins modulating cytoskeleton (e.g., nestin and palladin) directly correlate to the severity of the disease. Their defective presence may define proband-failure in balancing aberrances related to mutant collagen.     

A Novel Genetic Variant in the WFS1 Gene in a Patient with Partial Uniparental Mero-Isodisomy of Chromosome 4

Wolfram syndrome is a rare autosomal recessive disorder characterized by optic atrophy and diabetes mellitus. Wolfram syndrome type 1 (WFS1) is caused by bi-allelic pathogenic variations in the wolframin gene. We described the first case of WFS1 due to a maternal inherited mutation with uniparental mero-isodisomy of chromosome 4. Diabetes mellitus was diagnosed at 11 years of age, with negative anti-beta cells antibodies. Blood glucose control was optimal with low insulin requirement. No pathogenic variations in the most frequent gene causative of maturity-onset diabetes of the young subtypes were detected. At 17.8 years old, a rapid reduction in visual acuity occurred. Genetic testing revealed the novel homozygous variant c.1369A>G; p.Arg457Gly in the exon 8 of wolframin gene. It was detected in a heterozygous state only in the mother while the father showed a wild type sequence. In silico disease causing predictions performed by Polyphen2 classified it as “likely damaging”, while Mutation Tester and Sift suggested it was “polymorphism” and “tolerated”, respectively. High resolution SNP-array analysis was suggestive of segmental uniparental disomy on chromosome 4. In conclusion, to the best of our knowledge, we describe the first patient with partial uniparental mero-isodisomy of chromosome 4 carrying a novel mutation in the wolframin gene. The clinical phenotype observed in the patient and the analysis performed suggest that the genetic variant detected is pathogenetic.     

产气荚膜梭菌β_2毒素基因的克隆及定点突变

目的　克隆产气荚膜梭菌 β2 毒素基因 ,并选择可能影响其生物活性的氨基酸的相关碱基位点进行定点突变 ,构建β2 毒素基因的突变体。方法　利用PCR从C型产气荚膜梭菌基因组DNA中 ,扩增出约 0 7kb的基因 ,将其克隆至pGEM T载体上。经GOLDKEY软件分析抗原表位 ,PCR定点突变技术进行 2 34位半胱氨酸→苷氨酸的定点突变。结果　β2 毒素基因核苷酸序列与报道的一致 ,其突变基因 6 99位核苷酸由T→G。结论　已成功克隆了 β2 毒素基因 ,并准确实施了预期定点突变。     

CARD15/NOD2, CD14 and Toll-like 4 Receptor Gene Polymorphisms in Saudi Patients with Crohn's Disease

Crohn's disease (CD) is a multifactorial disease with a genetic component and an observed association with genes related to the innate immune response. Polymorphisms in the CARD15/NOD2 gene, in addition to functional variants of the toll-like receptor-4 (TLR4) and CD14 genes, have been associated with the development of Crohn's disease. There is no information about the frequency of these polymorphisms in the Saudi population. We examined the frequency of the three major CARD15/NOD2 risk alleles (Leu1007fsinsC, Arg702Trp, and Gly908Arg) and the TLR4 (Thr399Il) polymorphism as well as a functional polymorphism in the promoter of the CD14-159C/T in 46 Saudi CD patients and 50 matched controls. Genotyping was performed by allele-specific PCR or by restriction fragment length polymorphism (PCR-RFLP) analysis. The mutant genotype frequencies of the Leu1007fsinsC, Arg702Trp and Gly908Arg in the patient group were 6.5, 21.7 and 6.5%, respectively, compared with frequencies of 0, 4 and 2%, respectively, in the control group. There were 15 patients who carried the mutant alleles for all three CARD15/NOD2 variants, Leu1007fsinsC, Arg702Trp and Gly908Arg, while none of the control candidates carried the three alleles. This genetic study provides evidence that the three major CARD15/NOD2 variant alleles and the CD14 -159C/T polymorphism are associated with Crohn's disease (CD) susceptibility in the Saudi population; however, there is no evidence that the TLR4 (Thr399Il) or CARD15/NOD2 polymorphisms can be considered risk factors for Crohn's disease.     

Modification of S1 subsite specificity in the cysteine protease cathepsin B

Cysteine proteases of the papain family generally exhibit broadP₁ specificity. A notable exception is papaya proteinase IV(PPIV), which only accepts Gly at this position. In all othercysteine proteases the S₁ subsite residues 23 and 65 (papainnumbering) are absolutely conserved as Gly, while in PPIV theyare replaced by Glu and Arg, respectively. These differencesappear to underlie both PPIV specificity and its resistanceto inhibition by cystatins. To test this hypothesis, the equivalentresidues (Gly27 and Gly73) in the mammalian cysteine proteasecathepsin B were changed to Glu and Arg, respectively. Relativeto the wild-type enzyme, the Gly27Glu and Gly73Arg mutants showeda drastic reduction in activity with substrates containing aP₁ Arg. In contrast, substrates having a Gly residue in P₁ werehydrolyzed effectively. The double mutant (Gly27Glu:Gly73Arg)exhibited no detectable activity against any substrate studied.Inhibition of the Gly73Arg mutant by E-64 [1-(L-trans-epoxysuccinyl-L-leucylamino)-4-guanidinobutane]was found to be similar to that of the wild-type enzyme. Incontrast, inhibition by cystatin C exhibited a 20 000-fold reduction.These results demonstrate the dramatic influence of side chainsat sequence locations 27 and 73 on the S₁ subsite specificityof cysteine proteases.     

RPE65 c.353G>A,p.(Arg118Lys): A Novel Point Mutation Associated with Retinitis Pigmentosa and Macular Atrophy

Precise genetic diagnosis in RPE65-mediated retinitis pigmentosa (RP) is necessary to establish eligibility for genetic treatment with voretigene neparvovec: a recombinant adeno-associated viral vector providing a functional RPE65 gene. This case report aims to report a novel RP-related point mutation RPE65 c.353G>A, p.(Arg118Lys), a variant of uncertain significance associated with a severe clinical presentation and the striking phenotypic feature of complete macular atrophy. We report the case of a 40-year-old male with inherited retinal dystrophy, all features typical for the RPE65-associated RP, and marked macular atrophy. Genetic testing identified that the patient was a compound heterozygote in trans form with two heterozygous variants: RPE65 c.499G>T, p.(Asp167Tyr) and RPE65 c.353G>A, p.(Arg118Lys). Furthermore, short-wavelength and near-infrared autofluorescence patterns exhibited deficiencies specific to mutations in the visual cycle genes. To the best of our knowledge, RPE65 c.353G>A, p.(Arg118Lys) is the first described point mutation on this locus, among all other reported insertional mutations, currently classified as likely benign and of uncertain significance. We concluded that this variant contributed to the pathological phenotype, demonstrating its significance clearly to be reclassified as likely pathogenic. This being the case, patients with this specific variant in homozygous or compound heterozygous form would be likely candidates for genetic treatment with voretigene neparvovec.     

Morphology of Osteogenesis Imperfecta Collagen Mimetic Peptide Assemblies Correlates with the Identity of Glycine-Substituting Residue

Osteogenesis imperfecta (OI) is a hereditary bone disorder with various phenotypes ranging from mild multiple fractures to perinatal lethal cases, and it mainly results from the substitution of Gly by a bulkier residue in type I collagen. Triple-helical peptide models of Gly mutations have been widely utilized to decipher the etiology of OI, although these studies are mainly limited to characterizing the peptide features, such as stability and conformation in the solution state. Herein, we have constructed a new series of triple-helical peptides DD(GPO)₅ZPO(GPO)₄DD (Z=Ala, Arg, Asp, Cys, Glu, Ser, and Val) mimicking the most common types of observed OI cases. The inclusion of special terminal aspartic acids enables these collagen mimetic peptides to self-assemble to form nanomaterials upon the trigger of lanthanide ions. We have for the first time systematically evaluated the effect of different OI mutations on the aggregated state of collagen mimetic peptides. We have revealed that the identity of the Gly-substituting residue plays a determinant role in the morphology and secondary structure of the collagen peptide assemblies, showing that bulkier residues tend to result in a disruptive secondary structure and defective morphology, which lead to more severe OI phenotypes. These findings of osteogenesis imperfecta collagen mimetic peptides in the aggregation state provide novel perspectives on the molecular mechanism of osteogenesis imperfecta, and may aid the development of new therapeutic strategies.